- 专利标题： ALK7:ActRIIB heteromultimers and uses thereof
-
申请号： US17245123申请日： 2021-04-30
-
公开(公告)号： US11827689B2公开(公告)日： 2023-11-28
- 发明人: Ravindra Kumar , Asya Grinberg , Dianne Sako , Robert Scott Pearsall , Roselyne Castonguay , Gang Li , Yossi Dagon , John Knopf
- 申请人： Acceleron Pharma Inc.
- 申请人地址： US MA Cambridge
- 专利权人： ACCELERON PHARMA INC.
- 当前专利权人： ACCELERON PHARMA INC.
- 当前专利权人地址： US MA Cambridge
- 代理机构： White & Case LLP
- 主分类号： C07K14/71
- IPC分类号： C07K14/71 ; A61K38/00 ; A61K38/45 ; C12N9/12
摘要：
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
公开/授权文献
- US20220119491A1 ALK7:ACTRIIB HETEROMULTIMERS AND USES THEREOF 公开/授权日：2022-04-21
信息查询
